Profilo
Jennifer A.
Smith worked as a Biostatistics Director at Pharmacyclics LLC from 2000 to 2007.
She then worked as a Senior Director-Biometrics at Geron Corp.
from 2007 to 2010, and as a Senior Director-Biometrics at BiPar Sciences, Inc. from 2010 to 2011.
She later became the Vice President-Biometrics at Sunesis Pharmaceuticals, Inc. Dr. Smith received her undergraduate degree from the University of Toronto and her graduate and doctorate degrees from Stanford University.
Precedenti posizioni note di Jennifer A. Smith
| Società | Posizione | Fine |
|---|---|---|
BiPar Sciences, Inc.
 BiPar Sciences, Inc. Pharmaceuticals: MajorHealth Technology BiPar Sciences, Inc. develops and markets drugs for cancer patients. It offers BSI-201, a poly ADP-ribose polymerase (PARP) inhibitor for metastatic triple negative breast cancer, ovarian cancer, and other malignancies; BSI-401, a follow-on PARP inhibitor candidate for pancreatic cancer; and BSI-301, an iodothyronine program with anti-tubulin properties. The company was founded by Barry M. Sherman, Thomas F. White and Allan Basbaum in 2002 and is headquartered in Bridgewater, NJ. | Corporate Officer/Principal | 01/01/2011 |
| GERON CORPORATION | Corporate Officer/Principal | 01/01/2010 |
| PHARMACYCLICS, INC. | Corporate Officer/Principal | 01/01/2007 |
| VIRACTA THERAPEUTICS, INC. | Corporate Officer/Principal | - |
Formazione di Jennifer A. Smith
| Stanford University | Doctorate Degree |
| University of Toronto | Undergraduate Degree |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Società quotate in Borsa | 1 |
|---|---|
| GERON CORPORATION | Health Technology |
| Aziende private | 3 |
|---|---|
Sunesis Pharmaceuticals, Inc.
 Sunesis Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Sunesis Pharmaceuticals, Inc. engages in the development and commercialization of new oncology therapeutics for the treatment of solid and hematologic cancers. The firm's activities include conducting research and development internally and through corporate collaborators, in-licensing and out-licensing pharmaceutical compounds and technology, conducting clinical trials and raising capital. The company was founded on February 10, 1998 and is headquartered in South San Francisco, CA. | Health Technology |
BiPar Sciences, Inc.
BiPar Sciences, Inc. Pharmaceuticals: MajorHealth Technology BiPar Sciences, Inc. develops and markets drugs for cancer patients. It offers BSI-201, a poly ADP-ribose polymerase (PARP) inhibitor for metastatic triple negative breast cancer, ovarian cancer, and other malignancies; BSI-401, a follow-on PARP inhibitor candidate for pancreatic cancer; and BSI-301, an iodothyronine program with anti-tubulin properties. The company was founded by Barry M. Sherman, Thomas F. White and Allan Basbaum in 2002 and is headquartered in Bridgewater, NJ. | Health Technology |
Pharmacyclics LLC
 Pharmacyclics LLC Pharmaceuticals: MajorHealth Technology Pharmacyclics LLC engages in developing and commercializing innovative small-molecule drugs for the treatment of cancer and immune mediated diseases. It has product candidates in clinical development and several preclinical molecules in optimization. The company was founded by Jonathan Sessler and Richard Miller in 1991 and is headquartered in Sunnyvale, CA. | Health Technology |
- Borsa valori
- Insiders
- Jennifer A. Smith
